AV

Anil Vaijanathrao Gavali

Active Director Designated Partner DIN 10548619
DIN 10548619 First appointment Mar 2024 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2024
Shareholding value β€’β€’β€’β€’ Premium profile

About Anil Vaijanathrao Gavali

Data last updated:

Anil Vaijanathrao Gavali is a Designated Partner at Cranberries Pharmaceuticals Llp (since 2024). The company operates in Pharma.

DIN 10548619
Primary Designation Designated Partner
Industry Pharma
First Appointment 13 Mar 2024
Oldest Company Age 2 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Designated Partner13 Mar 20242024Active

Board colleagues of Anil Vaijanathrao Gavali

Directorship timeline

Open interactive timeline →
Cranberries Pharmaceuticals Llp
Premium access

Shareholding and investment profile for Anil Vaijanathrao Gavali

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Anil Vaijanathrao Gavali

Anil Vaijanathrao Gavali currently holds 1 directorship: Cranberries Pharmaceuticals Llp (Designated Partner, since 13 Mar 2024).

Anil Vaijanathrao Gavali was first appointed on 13 Mar 2024 as Designated Partner at Cranberries Pharmaceuticals Llp.

The current boards of Anil Vaijanathrao Gavali's companies include Krishna Ansiram Yadav (Cranberries Pharmaceuticals Llp), Mahesh Ramnath Phalke (Cranberries Pharmaceuticals Llp), Suresh Eknath Jangale (Cranberries Pharmaceuticals Llp).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available